303 related articles for article (PubMed ID: 26879132)
1. Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer.
Schmid G; Notaro S; Reimer D; Abdel-Azim S; Duggan-Peer M; Holly J; Fiegl H; Rössler J; Wiedemair A; Concin N; Altevogt P; Marth C; Zeimet AG
BMC Cancer; 2016 Feb; 16():102. PubMed ID: 26879132
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of folate receptor 1 (FOLR1) mRNA expression, its specific promoter methylation and global DNA hypomethylation in type I and type II ovarian cancers.
Notaro S; Reimer D; Fiegl H; Schmid G; Wiedemair A; Rössler J; Marth C; Zeimet AG
BMC Cancer; 2016 Aug; 16():589. PubMed ID: 27485273
[TBL] [Abstract][Full Text] [Related]
3. [Expression and significance of microRNAs in the p53 pathway in ovarian cancer cells and serous ovarian cancer tissues].
Zhang Q; He XJ; Ma LP; Li N; Yang J; Cheng YX; Cui H
Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):885-90. PubMed ID: 22340095
[TBL] [Abstract][Full Text] [Related]
4. Regulation of transcription factor E2F3a and its clinical relevance in ovarian cancer.
Reimer D; Hubalek M; Kiefel H; Riedle S; Skvortsov S; Erdel M; Hofstetter G; Concin N; Fiegl H; Müller-Holzner E; Marth C; Altevogt P; Zeimet AG
Oncogene; 2011 Sep; 30(38):4038-49. PubMed ID: 21516127
[TBL] [Abstract][Full Text] [Related]
5. Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas.
Vogt M; Munding J; Grüner M; Liffers ST; Verdoodt B; Hauk J; Steinstraesser L; Tannapfel A; Hermeking H
Virchows Arch; 2011 Mar; 458(3):313-22. PubMed ID: 21225432
[TBL] [Abstract][Full Text] [Related]
6. Promoter hypermethylation of miR-34a contributes to the risk, progression, metastasis and poor survival of laryngeal squamous cell carcinoma.
Shen Z; Zhou C; Li J; Ye D; Li Q; Wang J; Cui X; Chen X; Bao T; Duan S
Gene; 2016 Nov; 593(2):272-6. PubMed ID: 27450916
[TBL] [Abstract][Full Text] [Related]
7. p53-dependent activation of microRNA-34a in response to etoposide-induced DNA damage in osteosarcoma cell lines not impaired by dominant negative p53 expression.
Novello C; Pazzaglia L; Conti A; Quattrini I; Pollino S; Perego P; Picci P; Benassi MS
PLoS One; 2014; 9(12):e114757. PubMed ID: 25490093
[TBL] [Abstract][Full Text] [Related]
8. Inactivation of miR-34a by aberrant CpG methylation in Kazakh patients with esophageal carcinoma.
Cui X; Zhao Z; Liu D; Guo T; Li S; Hu J; Liu C; Yang L; Cao Y; Jiang J; Liang W; Liu W; Li S; Wang L; Wang L; Gu W; Wu C; Chen Y; Li F
J Exp Clin Cancer Res; 2014 Feb; 33(1):20. PubMed ID: 24528540
[TBL] [Abstract][Full Text] [Related]
9. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
[TBL] [Abstract][Full Text] [Related]
10. Novel miRNA genes deregulated by aberrant methylation in ovarian carcinoma are involved in metastasis.
Loginov VI; Pronina IV; Burdennyy AM; Filippova EA; Kazubskaya TP; Kushlinsky DN; Utkin DO; Khodyrev DS; Kushlinskii NE; Dmitriev AA; Braga EA
Gene; 2018 Jul; 662():28-36. PubMed ID: 29631007
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic inactivation of DAPK1, p14ARF, mir-34a and -34b/c in acute promyelocytic leukaemia.
Ng HY; Wan TS; So CC; Chim CS
J Clin Pathol; 2014 Jul; 67(7):626-31. PubMed ID: 24811488
[TBL] [Abstract][Full Text] [Related]
12. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer.
Lodygin D; Tarasov V; Epanchintsev A; Berking C; Knyazeva T; Körner H; Knyazev P; Diebold J; Hermeking H
Cell Cycle; 2008 Aug; 7(16):2591-600. PubMed ID: 18719384
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of miR-34a in breast tumors is not associated with either p53 mutations or promoter hypermethylation while it correlates with metastasis.
Javeri A; Ghaffarpour M; Taha MF; Houshmand M
Med Oncol; 2013 Mar; 30(1):413. PubMed ID: 23292869
[TBL] [Abstract][Full Text] [Related]
14. miR-34a inhibits the in vitro cell proliferation and migration in human esophageal cancer.
Shi H; Zhou S; Liu J; Zhu J; Xue J; Gu L; Chen Y
Pathol Res Pract; 2016 May; 212(5):444-9. PubMed ID: 26944831
[TBL] [Abstract][Full Text] [Related]
15. The association between miR-34 dysregulation and distant metastases formation in lung adenocarcinoma.
Daugaard I; Knudsen A; Kjeldsen TE; Hager H; Hansen LL
Exp Mol Pathol; 2017 Jun; 102(3):484-491. PubMed ID: 28512015
[TBL] [Abstract][Full Text] [Related]
16. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer.
Gallardo E; Navarro A; Viñolas N; Marrades RM; Diaz T; Gel B; Quera A; Bandres E; Garcia-Foncillas J; Ramirez J; Monzo M
Carcinogenesis; 2009 Nov; 30(11):1903-9. PubMed ID: 19736307
[TBL] [Abstract][Full Text] [Related]
17. Microvessel density and CpG island methylation of the THBS2 gene in malignant ovarian tumors.
Czekierdowski A; Czekierdowska S; Danilos J; Czuba B; Sodowski K; Sodowska H; Szymanski M; Kotarski J
J Physiol Pharmacol; 2008 Sep; 59 Suppl 4():53-65. PubMed ID: 18955754
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a p53/miR-34a/CSF1R/STAT3 Feedback Loop in Colorectal Cancer.
Shi X; Kaller M; Rokavec M; Kirchner T; Horst D; Hermeking H
Cell Mol Gastroenterol Hepatol; 2020; 10(2):391-418. PubMed ID: 32304779
[TBL] [Abstract][Full Text] [Related]
19. Methylation-associated silencing of microRNA-34b in hepatocellular carcinoma cancer.
Xie K; Liu J; Chen J; Dong J; Ma H; Liu Y; Hu Z
Gene; 2014 Jun; 543(1):101-7. PubMed ID: 24704024
[TBL] [Abstract][Full Text] [Related]
20. Evaluating L1CAM expression in human endometrial cancer using qRT-PCR.
Notaro S; Reimer D; Duggan-Peer M; Fiegl H; Wiedermair A; Rössler J; Altevogt P; Marth C; Zeimet AG
Oncotarget; 2016 Jun; 7(26):40221-40232. PubMed ID: 27233077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
